Median OS was 13.3 mo ( 9.2 , 16.3 ) in Arm A and 12.8 ( 6.5 , 16.1 ) in Arm B. Adverse events were not different than expected from standard chemotherapy , and comparable in the two arms , aside from infusion reactions which occurred in 70 % of patients treated with CBP501 .